NASDAQ:ANIK - Anika Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $35.71 +0.80 (+2.29 %) (As of 11/18/2018 05:55 AM ET)Previous Close$35.71Today's Range$34.3911 - $36.0552-Week Range$28.54 - $69.81Volume99,291 shsAverage Volume107,183 shsMarket Capitalization$507.47 millionP/E Ratio21.01Dividend YieldN/ABeta1.93 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Anika Therapeutics, Inc., together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company develops, manufactures, and commercializes therapeutic products based on its proprietary hyaluronic acid (HA) technology. Its orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, MONOVISC, and CINGAL for the treatment of osteoarthritis of the knee; HYALOFAST, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery; HYALONECT, a resorbable knitted fabric mesh; HYALOSS used to mix blood/bone grafts to form a paste for bone regeneration; and HYALOGLIDE, an ACP gel used in tenolysis treatment. The company's dermal products include wound care products that comprise HYALOMATRIX and HYALOFILL for the treatment of complex wounds, such as burns and ulcers, and for use in connection with the regeneration of skin; and ELEVESS, an aesthetic dermatology product. Its surgical products comprise HYALOBARRIER, a post-operative adhesion barrier for use in the abdomino-pelvic area; INCERT, a HA product used for the prevention of post-surgical spinal adhesions; MEROGEL, a woven fleece nasal packing; and MEROGEL INJECTABLE, a viscous hydrogel. The company also offers ophthalmic products, including injectable HA products that are used as viscoelastic agents in ophthalmic surgical procedures, such as cataract extraction and intraocular lens implantation; and veterinary products, which include HYVISC, an injectable HA product for the treatment of joint dysfunction in horses. Anika Therapeutics, Inc. has a strategic collaboration with the Institute for Applied Life Sciences at the University of Massachusetts Amherst to develop a therapy for rheumatoid arthritis. The company was founded in 1983 and is headquartered in Bedford, Massachusetts. Receive ANIK News and Ratings via Email Sign-up to receive the latest news and ratings for ANIK and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryHealth Care Supplies SectorMedical Current SymbolNASDAQ:ANIK Previous Symbol CUSIP03525510 Webwww.anikatherapeutics.com Phone781-457-9000 Debt Debt-to-Equity RatioN/A Current Ratio21.03 Quick Ratio18.47 Price-To-Earnings Trailing P/E Ratio21.01 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$113.42 million Price / Sales4.47 Cash Flow$2.3054 per share Price / Cash15.49 Book Value$17.96 per share Price / Book1.99 Profitability EPS (Most Recent Fiscal Year)$1.96 Net Income$31.81 million Net Margins17.66% Return on Equity9.78% Return on Assets9.14% Miscellaneous Employees123 Outstanding Shares14,210,000Market Cap$507.47 million OptionableOptionable Anika Therapeutics (NASDAQ:ANIK) Frequently Asked Questions What is Anika Therapeutics' stock symbol? Anika Therapeutics trades on the NASDAQ under the ticker symbol "ANIK." How were Anika Therapeutics' earnings last quarter? Anika Therapeutics Inc (NASDAQ:ANIK) released its earnings results on Wednesday, October, 24th. The biotechnology company reported $0.53 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.31 by $0.22. The biotechnology company earned $26.79 million during the quarter, compared to the consensus estimate of $27.12 million. Anika Therapeutics had a return on equity of 9.78% and a net margin of 17.66%. Anika Therapeutics's quarterly revenue was down 1.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.46 EPS. View Anika Therapeutics' Earnings History. When is Anika Therapeutics' next earnings date? Anika Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, February 20th 2019. View Earnings Estimates for Anika Therapeutics. What price target have analysts set for ANIK? 3 brokers have issued 1 year price objectives for Anika Therapeutics' stock. Their forecasts range from $34.00 to $48.00. On average, they expect Anika Therapeutics' stock price to reach $41.00 in the next year. This suggests a possible upside of 14.8% from the stock's current price. View Analyst Price Targets for Anika Therapeutics. What is the consensus analysts' recommendation for Anika Therapeutics? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Anika Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Anika Therapeutics. What are Wall Street analysts saying about Anika Therapeutics stock? Here are some recent quotes from research analysts about Anika Therapeutics stock: 1. According to Zacks Investment Research, "Anika Therapeutics, Inc. is a global, integrated orthopedic medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative cartilage repair. Anika's orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. " (10/29/2018) 2. Barrington Research analysts commented, "We expect gross margin to bounce back by a few hundred basis points as the year progresses." (5/4/2018) Has Anika Therapeutics been receiving favorable news coverage? News headlines about ANIK stock have trended somewhat positive on Sunday, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Anika Therapeutics earned a media sentiment score of 1.1 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. Who are some of Anika Therapeutics' key competitors? Some companies that are related to Anika Therapeutics include Tandem Diabetes Care (TNDM), Irhythm Technologies (IRTC), Mazor Robotics (MZOR), Atrion (ATRI), AtriCure (ATRC), K2M Group (KTWO), Nevro (NVRO), Luminex (LMNX), Cryolife (CRY), Orthofix Medical (OFIX), Tactile Systems Technology (TCMD), Cardiovascular Systems (CSII), Intersect ENT (XENT), AngioDynamics (ANGO) and SurModics (SRDX). Who are Anika Therapeutics' key executives? Anika Therapeutics' management team includes the folowing people: Mr. Joseph G. Darling, CEO, Pres & Director (Age 60)Ms. Sylvia Cheung, CFO, Treasurer & Sec. (Age 43)Dr. Edward S. Ahn, Chief Technology & Strategy Officer (Age 46)Mr. Richard Hague, Chief Commercial Officer (Age 58)Mr. Alexei Goraltchouk, VP of Operations Who are Anika Therapeutics' major shareholders? Anika Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (15.03%), Dimensional Fund Advisors LP (7.02%), First Manhattan Co. (2.81%), AMI Asset Management Corp (2.18%), Bank of New York Mellon Corp (2.00%) and Renaissance Technologies LLC (1.90%). Company insiders that own Anika Therapeutics stock include Charles H Sherwood, Jeffery S Thompson and Richard Hague. View Institutional Ownership Trends for Anika Therapeutics. Which institutional investors are selling Anika Therapeutics stock? ANIK stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, First Manhattan Co., Capital Management Corp VA, Renaissance Technologies LLC, AMI Asset Management Corp, Fisher Asset Management LLC, Thomson Horstmann & Bryant Inc. and AQR Capital Management LLC. View Insider Buying and Selling for Anika Therapeutics. Which institutional investors are buying Anika Therapeutics stock? ANIK stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Foundry Partners LLC, JPMorgan Chase & Co., JPMorgan Chase & Co., Rice Hall James & Associates LLC, Thompson Siegel & Walmsley LLC, Dimensional Fund Advisors LP and Teton Advisors Inc.. View Insider Buying and Selling for Anika Therapeutics. How do I buy shares of Anika Therapeutics? Shares of ANIK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Anika Therapeutics' stock price today? One share of ANIK stock can currently be purchased for approximately $35.71. How big of a company is Anika Therapeutics? Anika Therapeutics has a market capitalization of $507.47 million and generates $113.42 million in revenue each year. The biotechnology company earns $31.81 million in net income (profit) each year or $1.96 on an earnings per share basis. Anika Therapeutics employs 123 workers across the globe. What is Anika Therapeutics' official website? The official website for Anika Therapeutics is http://www.anikatherapeutics.com. How can I contact Anika Therapeutics? Anika Therapeutics' mailing address is 32 WIGGINS AVENUE, BEDFORD MA, 01730. The biotechnology company can be reached via phone at 781-457-9000 or via email at [email protected] MarketBeat Community Rating for Anika Therapeutics (NASDAQ ANIK)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 193 (Vote Outperform)Underperform Votes: 167 (Vote Underperform)Total Votes: 360MarketBeat's community ratings are surveys of what our community members think about Anika Therapeutics and other stocks. Vote "Outperform" if you believe ANIK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANIK will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 11/18/2018 by MarketBeat.com StaffFeatured Article: What impact do institutional investors have on markets?